{"id":44980,"date":"2024-12-09T21:17:00","date_gmt":"2024-12-09T20:17:00","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=44980"},"modified":"2024-12-15T21:18:02","modified_gmt":"2024-12-15T20:18:02","slug":"biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/","title":{"rendered":"Biosergen receives SEK 44.9M, Nordics outperfrom Danish stocks, Gubra set to top the year"},"content":{"rendered":"\n

NORDIC | BIOTECH & HEALTHCARE<\/strong> Your insights into listed Danish & Nordic biotech & healthcare stocks.<\/em><\/p>\n\n\n\n

In the past week, the Nordic biotech and healthcare stocks declined slightly by 0.7%, with the Danish ones falling 6.6% as DanCann Pharma lost two-thirds of its market cap. During the week, Biosergen<\/a><\/strong> raised MSEK 44.9, while ExpreS2ion<\/a><\/strong> raised MSEK 10, and received approval to initiate a phase I study for a vaccine candidate against HER2-expressing breast cancer. Finally, JP Morgan cut its price target for Genmab<\/a><\/strong> from DKK 2,050 to DKK 1,700, but the target is still higher than the current share price of DKK 1,546.<\/strong><\/p>\n\n\n\n

8 of the 22 Danish biotech companies had a positive share price development in the past week and 13 companies have had a positive share price performance year-to-date. Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance.<\/strong> 5 <\/strong><\/span>Danish healthcare stocks with +100% YTD return.<\/strong><\/p>\n\n\n\n

\n
Register for the Nordic I Impact newsletter here.<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Danish company news<\/strong><\/p>\n\n\n\n

Acarix AB<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Ascendis Pharma<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Biosergen<\/a><\/strong><\/p>\n\n\n\n

Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3 (Link<\/a>)<\/p>\n\n\n\n

Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3 (Link<\/a>)<\/p>\n\n\n\n

Cessatech<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

CS Medica<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Curasight<\/a><\/strong><\/p>\n\n\n\n

Curasight will announce the outcome of the exercise of its warrants of series TO2 today with the results yet to be announced by the company.<\/p>\n\n\n\n

DanCann Pharma<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Evaxion Biotech<\/a><\/strong><\/p>\n\n\n\n

Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

ExpreS2ion<\/a><\/strong><\/p>\n\n\n\n

ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Warrants of series TO 10 were exercised to approximately 69 percent and ExpreS2ion receives approximately SEK 10 million (Link<\/a>)<\/p>\n\n\n\n

Fluoguide<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Genmab<\/a><\/strong><\/p>\n\n\n\n

JP Morgan cut its price target from DKK 2,050 to DKK 1,700. <\/p>\n\n\n\n

Gubra<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Initiator Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

IO Biotech<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Pila Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Saniona<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Scandion Oncology<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

SynAct Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

ViroGates<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Zealand Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Y-mAbs Therapeutic<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

2cureX<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em>k<\/p>\n\n\n\n

Share price development \u2013 Danish stocks<\/strong><\/p>\n\n\n\n

On average, Danish biotech and healthcare stocks delivered a negative return of 6.6% after two weeks in a row with double-digit returns. There was notably little to no news in the past week, where many companies seemed to decline following low traded volume. Biosergen<\/a><\/strong>, however, raised MSEK 44.9, while ExpreS2ion<\/a><\/strong> received MSEK 10, and got approval to initiate a phase 1 study for a vaccine candidate against HER2-expressing breast cancer. Finally, JP Morgan cut its price target Genmab<\/a><\/strong> from DKK 2,050 to DKK 1,700, but it is still higher than the current share price of DKK 1,546. Two-thirds of the market value in DanCann Pharma<\/a><\/strong> was lost during the week without any news.<\/p>\n\n\n\n

Gubra<\/a><\/strong> continues to be the best-performing stock year-to-date with a return of 460%. Pila Pharma<\/a>, Saniona<\/a><\/strong>, Zealand Pharma<\/a><\/strong> and ViroGates<\/a><\/strong> have also generated more than a 100% return. <\/p>\n\n\n\n

Investment case for Curasight<\/a><\/strong><\/p>\n\n\n\n

Overview of share price development the past week, year-to-date, and the last twelve month<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Nordic Biotech & Healthcare Developments<\/mark><\/strong><\/p>\n\n\n\n

The <\/span>Kapital Partner Nordic Healthcare Index (KPHC) decreased by 0.7% to 64,01 in the past week. After a good start to the year, the index declined together with the other indexes from July to November, and now the indexes seem to be at a turning point testing higher grounds. The 1-year return for the KPHC index has almost been erased by the past months of poor performance.<\/p>\n\n\n\n

The Nordic healthcare stocks (KPHC) vs. C25, S30, and KPNGX the past year<\/strong><\/p>\n\n\n\n

\"\"
The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.<\/sup><\/figcaption><\/figure>\n\n\n\n

The top three best-performing stocks in the past week<\/strong><\/p>\n\n\n\n

Alteco Medical<\/a><\/strong> (99%)<\/strong> offers a medical device for extracorporeal blood purification. The product removes endotoxin (lipopolysaccharide, LPS) from the patient\u2019s bloodstream, and is applied as an add-on therapy in sepsis to treat endotoxemia (high levels of endotoxin). This can help stabilize the patient in acute situations. Endotoxemia is often present in sepsis, a life-threatening condition and one of the most common causes of death in modern intensive care. The stock rose following a distribution agreement with Medica S.p.A with exclusive rights to commercialize Alteco LPS adsorber in Italy, Germany, UK, France, Spain, and Switzerland running for 3 years.<\/p>\n\n\n\n

Eevia Health <\/a>(61%)<\/strong> is a life science company. The company offers production protocols and procedures for delivering organic products to international customers. The products are sold to corporate customers and include ingredients for manufacturers of dietary supplements, food, and cosmetics on a global basis. The products include, for example, blueberries, chaga mushrooms, and pine bark. <\/p>\n\n\n\n

Infant Bacterial Therapeutics<\/a> (60%)<\/strong> is a pharmaceutical company. The company develops drugs to treat and prevent children from developing common ailments and diseases that occur at premature birth. Common is that disorders can occur in the development of microorganisms such as microbiome. The largest operations are in the Nordic market.<\/p>\n\n\n\n

Resources: Refinitiv Eikon, Cision, Nordnet & company websites<\/strong><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks declined slightly by 0.7%, with the Danish ones falling 6.6% as DanCann Pharma lost two-thirds of its market cap. During the week, Biosergen raised MSEK 44.9, while ExpreS2ion raised MSEK […]<\/p>\n","protected":false},"author":2,"featured_media":43132,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[9,29,165,205],"tags":[],"class_list":["post-44980","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-en-investeringscases","category-investeringscases","category-investment-cases","category-news"],"acf":[],"yoast_head":"\nBiosergen receives SEK 44.9M, Nordics outperfrom Danish stocks, Gubra set to top the year | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biosergen receives SEK 44.9M, Nordics outperfrom Danish stocks, Gubra set to top the year | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks declined slightly by 0.7%, with the Danish ones falling 6.6% as DanCann Pharma lost two-thirds of its market cap. During the week, Biosergen raised MSEK 44.9, while ExpreS2ion raised MSEK […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-09T20:17:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-15T20:18:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"724\" \/>\n\t<meta property=\"og:image:height\" content=\"418\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kapital Partner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kapital Partner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/\"},\"author\":{\"name\":\"Kapital Partner\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/f79e57d92a60bb503a02eff0aadbe1fe\"},\"headline\":\"Biosergen receives SEK 44.9M, Nordics outperfrom Danish stocks, Gubra set to top the year\",\"datePublished\":\"2024-12-09T20:17:00+00:00\",\"dateModified\":\"2024-12-15T20:18:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/\"},\"wordCount\":905,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"articleSection\":[\"All investment Cases\",\"Investeringscases\",\"Investment cases\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/\",\"name\":\"Biosergen receives SEK 44.9M, Nordics outperfrom Danish stocks, Gubra set to top the year | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"datePublished\":\"2024-12-09T20:17:00+00:00\",\"dateModified\":\"2024-12-15T20:18:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"width\":724,\"height\":418},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"All investment Cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Biosergen receives SEK 44.9M, Nordics outperfrom Danish stocks, Gubra set to top the year\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/f79e57d92a60bb503a02eff0aadbe1fe\",\"name\":\"Kapital Partner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0ac4318887c096ae923f37487d5e98fd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0ac4318887c096ae923f37487d5e98fd?s=96&d=mm&r=g\",\"caption\":\"Kapital Partner\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biosergen receives SEK 44.9M, Nordics outperfrom Danish stocks, Gubra set to top the year | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/","og_locale":"en_US","og_type":"article","og_title":"Biosergen receives SEK 44.9M, Nordics outperfrom Danish stocks, Gubra set to top the year | Kapital Partner A\/S","og_description":"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks declined slightly by 0.7%, with the Danish ones falling 6.6% as DanCann Pharma lost two-thirds of its market cap. During the week, Biosergen raised MSEK 44.9, while ExpreS2ion raised MSEK […]","og_url":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2024-12-09T20:17:00+00:00","article_modified_time":"2024-12-15T20:18:02+00:00","og_image":[{"width":724,"height":418,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","type":"image\/jpeg"}],"author":"Kapital Partner","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Kapital Partner","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/"},"author":{"name":"Kapital Partner","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/f79e57d92a60bb503a02eff0aadbe1fe"},"headline":"Biosergen receives SEK 44.9M, Nordics outperfrom Danish stocks, Gubra set to top the year","datePublished":"2024-12-09T20:17:00+00:00","dateModified":"2024-12-15T20:18:02+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/"},"wordCount":905,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","articleSection":["All investment Cases","Investeringscases","Investment cases","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/","url":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/","name":"Biosergen receives SEK 44.9M, Nordics outperfrom Danish stocks, Gubra set to top the year | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","datePublished":"2024-12-09T20:17:00+00:00","dateModified":"2024-12-15T20:18:02+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","width":724,"height":418},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-receives-sek-44-9m-nordics-outperfrom-danish-stocks-gubra-set-to-top-the-year\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"All investment Cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/"},{"@type":"ListItem","position":3,"name":"Biosergen receives SEK 44.9M, Nordics outperfrom Danish stocks, Gubra set to top the year"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/f79e57d92a60bb503a02eff0aadbe1fe","name":"Kapital Partner","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0ac4318887c096ae923f37487d5e98fd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ac4318887c096ae923f37487d5e98fd?s=96&d=mm&r=g","caption":"Kapital Partner"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/44980"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=44980"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/44980\/revisions"}],"predecessor-version":[{"id":44981,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/44980\/revisions\/44981"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/43132"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=44980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=44980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=44980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}